Search Result

Results for "

b0011

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) ADC Payload (1) Androgen Receptor (2) Apoptosis (10) Autophagy (1) Caspase (1) COX (2) Cytochrome P450 (1) Drug Derivative (3) Drug Intermediate (1) Endogenous Metabolite (4) Endonuclease (2) ERK (1) Eukaryotic Initiation Factor (eIF) (1) HSP (1) Interleukin Related (2) Isotope-Labeled Compounds (2) MEK (2) Microtubule/Tubulin (9) NF-κB (2) Parasite (2) Peptide-Drug Conjugates (PDCs) (1) PERK (1) Pim (1) Reference Standards (4) Ser/Thr Kinase (1) Survivin (1)
By Research Areas:	Cancer (26) Infection (2) Inflammation/Immunology (2) Neurological Disease (1)

By Targets:

ADC Linker (1)

ADC Payload (1)

Androgen Receptor (2)

Apoptosis (10)

Autophagy (1)

Caspase (1)

COX (2)

Cytochrome P450 (1)

Drug Derivative (3)

Drug Intermediate (1)

Endogenous Metabolite (4)

Endonuclease (2)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

HSP (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

MEK (2)

Microtubule/Tubulin (9)

NF-κB (2)

Parasite (2)

Peptide-Drug Conjugates (PDCs) (1)

PERK (1)

Pim (1)

Reference Standards (4)

Ser/Thr Kinase (1)

Survivin (1)

By Research Areas:

Cancer (26)

Infection (2)

Inflammation/Immunology (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0011

Docetaxel 155+ Cited Publications RP-56976	Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011A

Docetaxel Trihydrate Maximum Cited Publications 158 Publications Verification RP-56976 Trihydrate	Microtubule/Tubulin Apoptosis	Cancer
Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

HY-B0011S

Docetaxel-d9 RP-56976-d₉	Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel-d₉ is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011R

Docetaxel (Standard) RP-56976 (Standard)	Reference Standards Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel (Standard) is the analytical standard of Docetaxel. This product is intended for research and analytical applications. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011AS

Docetaxel-d5 trihydrate RP-56976-d5 trihydrate	Isotope-Labeled Compounds Microtubule/Tubulin Apoptosis	Cancer
Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

HY-B0011AR

Docetaxel Trihydrate (Standard) RP-56976 Trihydrate (Standard)	Reference Standards Microtubule/Tubulin Apoptosis	Cancer
Docetaxel (Trihydrate) (Standard) is the analytical standard of Docetaxel (Trihydrate). This product is intended for research and analytical applications. Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

HY-B0022

Flutamide 10+ Cited Publications SCH 13521	Androgen Receptor	Cancer
Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .

HY-B0018

10-Acetyl docetaxel 2 Publications Verification PNU-101383	ADC Payload	Cancer
10-Acetyl docetaxel (PNU-101383) is an analog of Docetaxel (HY-B0011), with anticancer activity. 10-Acetyl docetaxel is a microtubule disassembly inhibitor, with antimitotic activity .

HY-115677

ILK-IN-3	Ser/Thr Kinase	Cancer
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .

HY-176835

PNR-3-80	Endonuclease Autophagy	Cancer
PNR-3-80 is an endonuclease G (ENDOG) inhibitor with an IC₅₀ of 0.67 μM. As a non-competitive binder to the ENDOG-substrate complex, PNR-3-80 specifically inhibits the endonuclease activity of ENDOG. PNR-3-80 reduces cell death induced by Cisplatin (HY-17394) and Docetaxel (HY-B0011), and inhibits DNA damage and autophagy (autophagy) induced by Etoposide (HY-13629). PNR-3-80 can be used in studies related to cell injury .

HY-N2434

[10]-Shogaol 5 Publications Verification	COX Interleukin Related NF-κB Parasite	Infection Inflammation/Immunology Cancer
[10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC₅₀ value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis .

HY-12929

NSC756093 SU093	Pim Apoptosis	Cancer
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a K_d of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .

HY-157942

CYP1B1-IN-7	Cytochrome P450	Cancer
CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC₅₀: 75 nM). CYP1B1-IN-7 also reverses resistance (IC₅₀: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .

HY-W653942

Docetaxel-d5 RP-56976-d₅	Endogenous Metabolite Microtubule/Tubulin Apoptosis Isotope-Labeled Compounds	Others
Docetaxel-d₅ is deuterium-labeled Docetaxel (HY-B0011) .

HY-P10757

DTX-P7	Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK	Cancer
DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .

HY-117404

LLS30	MEK ERK	Cancer
LLS30 is an anticancer agent. LLS30 suppresses MEK/ERK pathway. LLS30 has anti-cancer effects against ovarian cancer, prostate cancer, and malignant peripheral nerve sheath tumors. LLS30 shows synergistic anti-cancer effect with Enzalutamide (HY-70002) or Docetaxel (HY-B0011) .

HY-W019939

Hydroxy-PEG10-Boc	ADC Linker	Cancer
Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024) . Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011) .

HY-176780

Gαi2-IN-1	Others	Cancer
Gαi2-IN-1 (Compound 14) is a Gαi2 inhibitor. Gαi2-IN-1 significantly inhibits cancer cells migration induced by the chemotherapeutic drug, such as Vorinostat (HY-10221) and Docetaxel (HY-B0011). Gαi2-IN-1 can be used for cancers like prostate, breast and ovarian cancer research .

HY-176836

PNR-3-82	Endonuclease	Cancer
PNR-3-82 is a selective Apoptotic endonuclease G (EndoG) inhibitor with an IC₅₀ of 0.61  μM for EndoG over DNase I. PNR-3-82 does not inhibit five cell death-related enzymes including DNase II, RNase A, proteinase, lactate dehydrogenase and superoxide dismutase 1. PNR-3-82 has a cytoprotective activity and blocks Cisplatin (HY-17394) and Docetaxel (HY-B0011)-induced cell death. PNR-3-82 can be used for cell injuries research .

HY-W778546

7-epi-10-Deacetyl baccatin III	Others	Cancer
7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-W778547

7-epi-10-Oxo-10-deacetyl baccatin III 10-Dehydrobaccatin V	Drug Intermediate	Cancer
7-epi-10-Oxo-10-deacetyl baccatin III (10-Dehydrobaccatin V) can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-13684

Milataxel MAC-321	Drug Derivative Microtubule/Tubulin	Cancer
Milataxel (MAC-321) is an orally active taxane analog of Docetaxel (HY-B0011). Milataxel enhances the rate of tubulin polymerization. Milataxel can be used in the research of colorectal cancer and non-small cell lung cancer .

HY-136630

Felotaxel SHR110008	Drug Derivative	Others
Felotaxel (SHR110008) is a derivate of Docetaxel (HY-B0011), with antitumor activity and specific pharmacokinetic properties in rats. Felotaxel is rapidly distributed to normal tissues. The kidney is the major excretion organ, and its plasma protein binding capacity is nearly linearly related to concentration.

HY-119001

BKM1644	Survivin	Cancer
BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .

HY-B0022R

Flutamide (Standard) SCH 13521 (Standard)	Reference Standards Androgen Receptor	Cancer
Flutamide (Standard) is the analytical standard of Flutamide. This product is intended for research and analytical applications. Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .

HY-N2434R

[10]-Shogaol (Standard)	Reference Standards COX Interleukin Related NF-κB Parasite	Infection Inflammation/Immunology Cancer
-Shogaol (Standard) is the analytical standard of -Shogaol (HY-N2434). This product is intended for research and analytical applications. [10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC₅₀ value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis .

HY-176781

1-Deoxyceramide (m18:1/20:0)	Drug Derivative	Neurological Disease
1-Deoxyceramide (m18:1/20:0) is a type of ceramide. 1-Deoxyceramide (m18:1/20:0) is upregulated in the dorsal root ganglia of mice treated with Docetaxel (HY-B0011) .

HY-16457

Simotaxel MST 997	Microtubule/Tubulin Caspase Apoptosis	Cancer
Simotaxel (MST 997) is an orally active derivative of the taxane class. Simotaxel binds to β-tubulin and promotes tubulin polymerization (EC₅₀ = 0.9 μM), inhibits tubulin depolymerization, and causes cell cycle arrest at the G₂-M phase. Simotaxel disrupts the formation of the mitotic spindle and triggers the caspase-dependent apoptotic pathway (apoptosis). Simotaxel has inhibitory effects on Paclitaxel (HY-B0015) sensitive cell lines and overcomes drug resistance. Simotaxel can be used to study Paclitaxel / Docetaxel (HY-B0011) resistant solid tumors .

DTX-P7	Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK	Cancer
DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0011

Docetaxel 155+ Cited Publications RP-56976	Structural Classification Classification of Application Fields Terpenoids Diterpenoids Endogenous metabolite Disease Research Fields Source Classification Cancer	Microtubule/Tubulin Apoptosis Endogenous Metabolite
Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011R

Docetaxel (Standard) RP-56976 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Microtubule/Tubulin Apoptosis Endogenous Metabolite
Docetaxel (Standard) is the analytical standard of Docetaxel. This product is intended for research and analytical applications. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-N2434

[10]-Shogaol 5 Publications Verification	Zingiber officinale Roscoe Structural Classification Monophenols Classification of Application Fields Phenols Plants Disease Research Fields Source Classification Zingiberaceae Cancer	COX Interleukin Related NF-κB Parasite
[10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC₅₀ value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis .

HY-W778546

7-epi-10-Deacetyl baccatin III	Terpenoids Taxaceae Diterpenoids Plants Taxus baccata L. Source Classification	Others
7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-W778547

7-epi-10-Oxo-10-deacetyl baccatin III 10-Dehydrobaccatin V	Terpenoids Taxaceae Diterpenoids Plants Taxus baccata L. Source Classification	Drug Intermediate
7-epi-10-Oxo-10-deacetyl baccatin III (10-Dehydrobaccatin V) can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-N2434R

[10]-Shogaol (Standard)	Zingiber officinale Roscoe Structural Classification Monophenols Phenols Plants Source Classification Zingiberaceae	Reference Standards COX Interleukin Related NF-κB Parasite
-Shogaol (Standard) is the analytical standard of -Shogaol (HY-N2434). This product is intended for research and analytical applications. [10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC₅₀ value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis .

Cat. No.	Product Name	Chemical Structure

HY-B0011S

Docetaxel-d9
Docetaxel-d₉ is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011AS

Docetaxel-d5 trihydrate
Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

Docetaxel-d5 trihydrate

Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

HY-W653942

Docetaxel-d5
Docetaxel-d₅ is deuterium-labeled Docetaxel (HY-B0011) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

b0011

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products